Scarica l'app Stockscreener
2.13
9.75%
-0.23
Precedente Chiudi:
$2.36
Aprire:
$2.37
Volume 24 ore:
358.26K
Relative Volume:
0.69
Capitalizzazione di mercato:
$146.89M
Reddito:
$8.38M
Utile/perdita netta:
$-27.19M
Rapporto P/E:
-1.9541
EPS:
-1.09
Flusso di cassa netto:
$-13.59M
1 W Prestazione:
-6.99%
1M Prestazione:
+13.30%
6M Prestazione:
+119.59%
1 anno Prestazione:
+108.82%
Intervallo 1D:
$2.13
$2.4169
Intervallo di 1 settimana:
$2.13
$2.5907
Portata 52W:
$0.65
$2.5907
Opus Genetics Inc Stock (IRD) Company Profile
Nome
Opus Genetics Inc
Settore
Industria
Telefono
248-681-9815
Indirizzo
8 DAVIS DRIVE, DURHAM
Confronta IRD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
2.13 | 162.76M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Iniziato | B. Riley Securities | Buy |
| 2025-11-25 | Iniziato | Piper Sandler | Overweight |
| 2025-10-29 | Iniziato | Wedbush | Outperform |
| 2025-10-16 | Iniziato | Chardan Capital Markets | Buy |
| 2025-04-11 | Iniziato | Craig Hallum | Buy |
| 2024-11-13 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Opus Genetics Inc Borsa (IRD) Ultime notizie
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Director Sells 4,000,000 Shares of Stock - MarketBeat
Foundation Fighting Blindness Retinal Degeneration Fund Sells 4,000,000 Shares of Opus Genetics Inc (IRD) - GuruFocus
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) By Investing.com - Investing.com Australia
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) - Investing.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference | Associated Press | syndication news - Enidnews.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewswire
Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27% - simplywall.st
B. Riley Securities Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
B. Riley Initiates Opus Genetics at Buy With $9 Price Target - marketscreener.com
B.Riley initiates Opus Genetics stock with Buy rating on gene therapy potential - Investing.com Canada
Opus Genetics Says Independent Panel Backs Phase 1/2 Trial in Best Disease After Safety Review - marketscreener.com
Opus Genetics rises on update from eye disease study (IRD) - Seeking Alpha
Opus Genetics (IRD) Advances in Clinical Trial for Best Disease Treatment - GuruFocus
Opus Genetics advances Best disease gene therapy trial after positive safety review - Investing.com Canada
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease - marketscreener.com
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Is Opus Genetics Inc. stock positioned well for digital economy2025 Earnings Impact & Daily Market Momentum Tracking - Newser
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Opus Genetics Inc. (R3X1) stock trades after rate cutsMarket Risk Analysis & Smart Allocation Stock Reports - Newser
Why Opus Genetics Inc. (R3X1) stock gets analyst attentionOptions Play & High Accuracy Trade Signal Alerts - Newser
Equities Analysts Offer Predictions for Opus Genetics FY2025 Earnings - MarketBeat
How Opus Genetics Inc. (R3X1) stock trades under stagflationAnalyst Downgrade & Fast Entry High Yield Stock Tips - Newser
Why institutional investors increase stakes in Opus Genetics Inc. (R3X1) stockMarket Growth Summary & Verified Entry Point Signals - Newser
Will Opus Genetics Inc. (R3X1) stock outperform small cap peers2025 Market WrapUp & Growth Focused Stock Reports - Newser
Brokers Issue Forecasts for Opus Genetics FY2025 Earnings - Defense World
Opus Genetics (NASDAQ:IRD) Upgraded to "Strong-Buy" at Brookline Capital Management - MarketBeat
Why Opus Genetics Inc. stock remains on buy listsJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - Newser
Brookline Capital Management Upgrades Opus Genetics (NASDAQ:IRD) to Strong-Buy - Defense World
Opus Genetics, Inc. (IRD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Why Opus Genetics Inc. (R3X1) stock remains stable2025 Technical Patterns & Long-Term Growth Portfolio Plans - Newser
Will Opus Genetics Inc. (R3X1) stock test record highs in 2025Weekly Profit Summary & Long-Term Capital Growth Strategies - Newser
Brookline Capital Markets initiates Buy rating on Opus Genetics stock By Investing.com - Investing.com Canada
Opus Genetics, Inc.'s (NASDAQ:IRD) large institutional owners must be happy as stock continues to impress, up 12% over the past week - simplywall.st
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT - Insider Monkey
Opus Genetics (NASDAQ:IRD) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
12 Hot Penny Stocks to Invest in Right Now - Insider Monkey
Opus Genetics (NASDAQ:IRD) Coverage Initiated at Piper Sandler - MarketBeat
Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail
Piper Sandler Initiates Coverage on IRD with Overweight Rating a - GuruFocus
Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage - TradingView
Piper Sandler initiates coverage on Opus Genetics stock with Overweight rating - Investing.com Canada
Opus Genetics, Inc. $IRD is BIOS Capital Management LP’s 2nd Largest Position - Defense World
Opus Genetics Inc R3X1 Stock Analysis and ForecastCurrency Fluctuation Impact & Consistent High Yield Stocks - earlytimes.in
Opus Genetics, Inc. $IRD is BIOS Capital Management LP's 2nd Largest Position - MarketBeat
Opus Genetics’ New Study on Vision Improvement: What Investors Need to Know - MSN
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Bristol-Myers Squibb (BMY) and PACS Group Inc (PACS) - The Globe and Mail
How Opus Genetics Inc. (R3X1) stock reacts to fiscal policies2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
Is Opus Genetics Inc. (R3X1) stock a safe buy pre earningsJuly 2025 Patterns & Verified Technical Signals - newser.com
What is the fair value estimate for Opus Genetics Inc. (R3X1) stock in 2025Take Profit & Risk Controlled Daily Trade Plans - newser.com
Opus Genetics Inc Azioni (IRD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):